Adial Pharmaceuticals Inc logo

Adial Pharmaceuticals Inc

ADIL
Last price US$2.86
Market cap US$4.2m
12M price change -77.57%
Loading the 12-month Mave Thesis and 1-month news signal

Dashboard Funda..tals Prediction Screener Map

Adial Pharmaceuticals Inc Overview

Industry: Biotechnology

Sector: Healthcare

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcoho Read More

Mavefund brings filings, fundamentals, valuation, price history and news for Adial Pharmaceuticals Inc into one research view. The sections below show what strengthens or weakens the research case.

Score

Reported Results

What the company reported, with filing details kept small.

Filed May 11, 2026

Quarterly result summary

Net loss was -$2M (from $2.2M). Cash was $4.6M.

Net loss -$2M from $2.2M
Cash $4.6M reported

What changed

  • Net loss was -$2M (from $2.2M).

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

Earnings release Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

| Associated Press Of Pakistan

Principal Information Officer Raisa Adil being presented with a shield at the National Press Club by President Abdul Razzaq Sial and Finance Secretary Abid Abbasi on her arrival at the National Press Club.

Headline from | Associated Press Of Pakistan: Principal Information Officer Raisa Adil being presented with a shield at the National Press Club by President Abdul Razzaq Sial and Finance Secretary Abid Abbasi on her arrival at the National Press Club.

Earnings Per Share

Score 1.00/5
Adial Pharmaceuticals Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Return on Equity

Score 0.08/5
Adial Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Adial Pharma... ADIL US$4.2m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Net Margin

Score 2.21/5
Adial Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Adial Pharma... ADIL US$4.2m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Share Buyback

In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Leverage

Score 3.08/5
Adial Pharmaceuticals Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Adial Pharma... ADIL US$4.2m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

Verified SEC statements load when this section enters view.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Adial Pharmaceuticals Inc logo

Adial Pharmaceuticals Inc

US$2.86

US$4.2m

4.76%

-77.57%